Although sulfonylureas have long been therapeutically utilized for their hypoglycemic properties in type 2 diabetic patients, there is a paucity of clinical or experimental data that suggests that this pharmacotherapeutic class confers a benefit on the course of diabetic renal disease. Because the mesangial compartment is central to the fibrogenic response that evolves during the course of diabetic nephropathy, determining the metabolic influence of sulfonylureas on mesangial cells is important. In this article, the current knowledge regarding the metabolic and functional consequences of a mesangial triumvirate of sulfonylureas, their sulfonylurea receptors and sulfonylurea-like ligands termed endosulfines will be reviewed.

Keywords:
Mesangial cell, Sulfonylureas, Sulfonylurea receptor, Glucose transporter, Endosulfine
1.
Davidson M: Oral diabetic agents; in Diabetes Mellitus: Diagnosis and Treatment, ed 4. Philadelphia, Saunders, 1998, pp 127–140.
2.
Carpenter AM, Goetz FC, LeCompte PM, Williamson JR: Glomerulosclerosis in type 2 (non-insulin-dependent) diabetes mellitus: Relationship to glycaemia in the University Group Diabetes Program (UGDP). Diabetologia 1993;36:1057–1063.
3.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853.
4.
Ayo SH, Radnik RA, Garoni JA, Glass WF II, Kreisberg JI: High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 1990;136:1339–1348.
5.
Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994;93:536–542.
6.
Riser BL, Cortes P, Yee J, Sharba AK, Asano K, Rodríguez-Barbero A, Narins RG: Mechanical strain- and high glucose-induced alterations in mesangial cell collagen metabolism: Role of TGF-β. J Am Soc Nephrol 1997;9:827–836.
7.
Cortes P, Riser BL, Narins RG: Glomerular hypertension and progressive renal disease: The interplay of mesangial cell strech, cytokine formation and extracellular matrix synthesis. Contrib Nephrol 1996;118:229–233.
8.
Riser BL, DeNichilo M, Cortes P, Baker C, Yee J: Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in diabetic glomerulosclerosis. J Am Soc Nephrol 2000;11:25–38.
9.
Yee J: Plasma matrix metalloproteinase-9 and diabetic microalbuminuria: Tip of the iceberg? Am J Kidney Dis 1998;32:669–671.
10.
Cortes P, Riser BL, Asano K, Rodríguez-Barbero A, Narins RG, Yee J: Effects of oral antihyperglycemic agents on extracellular matrix synthesis by mesangial cells. Kidney Int 1998;54:1985–1998.
11.
Heilig C, Zaloga C, Lee M, Zhao X, Riser B, Brosius F, Cortes P: Immunogold localization of high-affinity glucose transporter isoforms in normal rat kidney. Lab Invest 1995;73:674–684.
12.
Inoki K, Haneda M, Maeda S, Koya D, Kikkawa R: TGF-β1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int 1999;55:1704–1712.
13.
Routh ER, Johnson JH, McCarthy KJ: Direct action of troglitazone on mesangial behavior: troglitazone suppresses the secretion of type 1 collagen by mesangial cells in vitro. Kidney Int in press.
14.
McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH: Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 2000;58:2341–2350.
15.
Babenko AP, Aguilar-Bryan L, Bryan J: A view of SUR/KIR6.X, KATP channels. Annu Rev Physiol 1998;60:667–687.
16.
Higgins CF: The ABC of channel regulation. Cell 1995;82:693–696.
17.
Chutkow WA, Simon MC, Le Beau MM, Burant CF: Cloning tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes 1996;45:1439–1445.
18.
Babenko AP, Gonzalez G, Aguilar-Bryan L, Bryan J: Reconstituted human cardiac KATP channels: Functional identity with the native channels from the sarcolemma of human ventricular cells. Circ Res 1998;83:1132–1143.
19.
Beesley AH, Qureshi IZ, Giesberts AN, Parker AJ, White SJ: Expression of sulphonylurea receptor protein in mouse kidney. Pflugers Arch 1999;438:1–7.
20.
Tanemoto M, Vanoye CG, Dong K, Welch R, Abe T, Herbert SC, Xu JZ: Rat homolog of sulfonylurea receptor 2B determines glibenclamide sensitivity of ROMK2 in Xenopus laevis oocyte. Am J Physiol Renal Physiol 2000;278:F659–F666.
21.
Asano K, Cortes P, Riser BL, Szamosfalvi B, Rodríguez-Barbero A, Yee J: Characterization of the rat mesangial cell type 2 sulfonylurea receptor. Kidney Int 1999;55:2289–2298.
22.
Szamosfalvi B, Cortes P, Alviani R, Riser BL, Zasuwa G, Yee J: Putative subunits of the rat mesangial KATP: a type 2B sulfonylurea receptor (SUR2B) and an inwardly-rectifying K+ channel (Kir6.1). Kidney Int, in press.
23.
Loessberg P, Zhao H, Muallen S: Synchronized oscillation of Ca2+ entry and Ca2+ release in agonist-stimulated AR42J cells. J Biol Chem 1991;266:1363–1366.
24.
Whiteside CI, Hurst RD, Stevanovic ZS: Calcium signaling and contractile response of diabetic glomerular mesangial cells. Kidney Int Supp. 1005;51:S28–S33.
25.
Cortes P, Mendez M, Riser BL, Guerín C, Rodríguez-Barbero A, Rucker C, Yee J: F-actin fiber distribution in glomerular cells and functional implications. Kidney Int 2000;58:2452–2461.
26.
Cortes P, Riser BL: The nature of the glomerulus: Pressure-induced metabolic alterations; in Mogenson CE (ed): The Kidney and Hypertension in Diabetes Mellitus. Boston, Kluwer, 1996, pp 119–124.
27.
Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612–619.
28.
Ikenaga H, Bast JP, Fallet RW, Carmines PK: Exaggerated impact of ATP-sensitive K+ channels on afferent arteriolar diameter in diabetes mellitus. J Am Soc Nephrol 2000;11:1199–1207.
29.
Virsolvy-Vergíne A, Leray H, Kuroki S, Lupo B, Dufour M, Bataille D: Endosulfine, an endogenous peptidic ligand for the sulfonylurea receptor: Purification and partial characterization from ovine brain. Proc Natl Acad Sci USA 1992;89:6629–6633.
30.
Héron L, Virsolvy A, Peyrollier K, Gribble FM, Le Cam A, Ashcroft FM, Bataille D: Human alpha-endosulfine, a possible regulator of sulfonylurea-sensitive KATP channel: Molecular cloning, expression and biological properties. Proc Natl Acad Sci USA 1998;95:8387–8391.
31.
Héron L, Virsolvy A, Apiou F, Le Cam A, Bataille D: Isolation, characterization, and chromosomal localization of the human ENSA gene that encodes alpha-endosulfine, a regulator of beta-cell KATP channel. Diabetes 1999;48:1873–1876.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.